A. Sætersdal

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

B. Naume, T. Risberg, I. Mjaaland, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

F. Markowetz, A. Børresen-Dale, Daniel Nebdal, 2018, bioRxiv.

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

R. Gelber, M. Piccart, J. Lee, 2021, Breast.

Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy

A. Børresen-Dale, V. Kristensen, Grethe I. Grenaker Alnæs, 2014, International journal of cancer.

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors

F. Markowetz, A. Børresen-Dale, K. Polyak, 2018, bioRxiv.

Abstract P1-08-21: Detection and monitoring of circulating endothelial cells, circulating tumor cells and disseminated tumor cells during neoadjuvant breast cancer treatment including bevacizumab

B. Naume, A. Fangberget, E. Borgen, 2013 .

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

R. Gelber, M. Piccart, J. Lee, 2023, The New England journal of medicine.

Abstract P3-05-04: Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer

K. Polyak, H. Russnes, B. Naume, 2012 .